Mixed Nanoscale Liposomes Co-Encapsulating Curcumin and Berberine Inhibit Activated Hepatic Stellate Cell-Induced Drug Resistance and Tumor Metastasis
Source abstract
Abstract
The combination therapy based on nanoscale materials has been proven an effective approach for cancer treatment. In this study, berberine (BBR) and curcumin (CUR) were loaded into mixed liposomes (CUR-GL/BBR-HL). To simulate a tumor microenvironment (TME), the dual-cell research model (SMMC7721 + LX-2) and orthotopic tumor-bearing mice model were established for antiproliferation and antimetastasis evaluation. The results showed that the mixed liposomes exhibited strong cytotoxicity and antimigration effect against the dual-cell research model. Notably, CUR-GL/BBR-HL effectively inhibited the activation of hepatic stellate cells (HSCs), extracellular matrix deposition, and tumor angiogenesis in vivo, resulting in an enhanced anticancer effect. The anti-HCC mechanism revealed that CUR-GL/BBR-HL could inhibit drug resistance and the metastasis of tumor cells by downregulating the expression of P-gp and vimentin, respectively. Hence, the combined therapeutic strategy could effectively inhibit cancer growth, and CUR-GL/BBR-HL might be a potential formulation for anticancer therapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Berberine and alkaloids research · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Nursing, Weifang University of Science and Technology, Weifang262700, P.R.China
School of Nursing, Weifang Medical University, Weifang261053, P.R.China
Department of Dermatology, Weifang People’s Hospital, Weifang261000, P.R.China
Department of Oncology, Weifang People’s Hospital, Weifang262700, P.R.China
School of Clinical Medicine, Weifang Medical University, Weifang261053, P.R.China
Funding
Weifang University of Science and Technology · National Natural Science Foundation of China
References (38)
Show source-provided references
1. 10.1016/j.jconrel.2016.12.04210.1016/j.jconrel.2016.12.042 ↗
2. 10.1007/s11684-019-0724-610.1007/s11684-019-0724-6 ↗
3. 10.1007/s00109-015-1283-110.1007/s00109-015-1283-1 ↗
4. 10.1007/s12079-019-00525-710.1007/s12079-019-00525-7 ↗
5. 10.3390/ijms1707103610.3390/ijms17071036 ↗
6. 10.1016/j.actbio.2019.09.03410.1016/j.actbio.2019.09.034 ↗
7. 10.1186/s13045-019-0739-010.1186/s13045-019-0739-0 ↗
8. 10.1016/j.canlet.2020.11.02510.1016/j.canlet.2020.11.025 ↗
9. 10.1016/j.ccell.2016.09.00410.1016/j.ccell.2016.09.004 ↗
10. 10.1139/cjpp-2018-055510.1139/cjpp-2018-0555 ↗
11. 10.1016/j.addr.2015.10.01310.1016/j.addr.2015.10.013 ↗
12. 10.1016/j.cell.2018.01.00910.1016/j.cell.2018.01.009 ↗
13. 10.1016/j.biomaterials.2017.09.02710.1016/j.biomaterials.2017.09.027 ↗
14. 10.1016/j.actbio.2018.06.01210.1016/j.actbio.2018.06.012 ↗
15. 10.1021/acsnano.8b0783010.1021/acsnano.8b07830 ↗
16. 10.1021/acsami.7b1824510.1021/acsami.7b18245 ↗
17. 10.1016/j.biomaterials.2018.01.04310.1016/j.biomaterials.2018.01.043 ↗
18. 10.1021/nn502861t10.1021/nn502861t ↗
19. 10.1021/acssynbio.9b0034910.1021/acssynbio.9b00349 ↗
20. 10.1021/acsami.7b1449610.1021/acsami.7b14496 ↗
21. 10.1021/acsnano.9b0416610.1021/acsnano.9b04166 ↗
22. 10.1016/j.biomaterials.2021.12100310.1016/j.biomaterials.2021.121003 ↗
23. 10.2147/IJN.S18897110.2147/IJN.S188971 ↗
24. 10.1021/acsami.2c1044610.1021/acsami.2c10446 ↗
25. 10.1016/j.ijpharm.2022.12171410.1016/j.ijpharm.2022.121714 ↗
26. 10.1016/j.lfs.2018.03.04610.1016/j.lfs.2018.03.046 ↗
27. 10.1016/j.actbio.2018.02.00410.1016/j.actbio.2018.02.004 ↗
28. 10.3892/ol.2017.754110.3892/ol.2017.7541 ↗
29. 10.1038/s41419-020-2613-y10.1038/s41419-020-2613-y ↗
30. 10.1002/jcp.2954510.1002/jcp.29545 ↗
31. 10.1371/journal.pone.018002310.1371/journal.pone.0180023 ↗
32. 10.1016/j.ijpharm.2020.11999310.1016/j.ijpharm.2020.119993 ↗
33. 10.1038/nrd.2016.19310.1038/nrd.2016.193 ↗
34. 10.1016/j.canlet.2014.10.02110.1016/j.canlet.2014.10.021 ↗
35. 10.1002/hep.3019310.1002/hep.30193 ↗
36. 10.1002/hep.3066810.1002/hep.30668 ↗
37. 10.1002/smll.20130358810.1002/smll.201303588 ↗
38. 10.1016/j.ccell.2019.08.00710.1016/j.ccell.2019.08.007 ↗